Enomoto Minori, Inoue Yuichi, Namba Kazuyoshi, Munezawa Takashi, Matsuura Masato
Japan Somnology center, Neuropsychiatric Research Institute, Tokyo, Japan.
Mov Disord. 2008 Apr 30;23(6):811-6; quiz 926. doi: 10.1002/mds.21882.
This study was done to identify the clinical characteristics of uremic restless legs syndrome (RLS). Consecutive uremic RLS patients (n = 15) and idiopathic RLS patients (iRLS; n = 20) were evaluated. The groups were compared with respect to their clinical course, subjective symptoms [using the Pittsburgh Sleep Quality Index (PSQI) and the International Restless Legs Syndrome Severity Scale (IRLS)], polysomnographic (PSG) variables, the results of the suggested immobilization test (SIT), and the drug doses used to treat RLS. The duration of the disorder was significantly shorter in the uremic RLS group than in the iRLS group. The PSQI and IRLS scores before treatment were higher in the uremic RLS group than in the iRLS group. The periodic leg movement index (PLM index) on PSG and the SIT index were also higher in the uremic RLS group (P < 0.001, respectively). The bromocriptine equivalent dose of dopaminergic agonists used to treat RLS was significantly higher in the uremic RLS group (P < 0.001). Uremic RLS appears to deteriorate faster and to become more severe than iRLS. Moreover, uremic RLS patients appear to have a decreased response to dopaminergic agonists.
本研究旨在确定尿毒症性不安腿综合征（RLS）的临床特征。对连续性尿毒症性RLS患者（n = 15）和特发性RLS患者（iRLS；n = 20）进行了评估。比较了两组患者的临床病程、主观症状[采用匹兹堡睡眠质量指数（PSQI）和国际不安腿综合征严重程度量表（IRLS）]、多导睡眠图（PSG）变量、推荐的制动试验（SIT）结果以及用于治疗RLS的药物剂量。尿毒症性RLS组的疾病持续时间明显短于iRLS组。治疗前，尿毒症性RLS组的PSQI和IRLS评分高于iRLS组。尿毒症性RLS组的PSG周期性腿部运动指数（PLM指数）和SIT指数也更高（P均< 0.001）。尿毒症性RLS组用于治疗RLS的多巴胺能激动剂的溴隐亭等效剂量明显更高（P < 0.001）。尿毒症性RLS似乎比iRLS恶化得更快且更严重。此外，尿毒症性RLS患者对多巴胺能激动剂的反应似乎有所降低。
